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Angiogenesis and endothelial activation and dysfunction have been associated with
acute graft-vs.-host disease (aGVHD), pointing to the endothelium as a potential target for
pharmacological intervention. Defibrotide (DF) is a drug with an endothelium-protective
effect that has been approved for the treatment of veno-occlusive disease/sinusoidal
obstruction syndrome after allogeneic hematopoietic cell transplantation. Clinical data
suggest that DF also reduces the incidence of aGVHD; however, the mechanisms
of DF-mediated aGVHD regulation have not been examined. To investigate possible
DF-mediated prophylactic and therapeutic mechanisms in aGVHD, we performed in
vitro studies using endothelial cell (EC) lines. We found that DF significantly and
dose-dependently suppressed EC proliferation and notably reduced their ability to form
vascular tubes in Matrigel. To explore whether DF administered prophylactically or
therapeutically has a significant effect on aGVHD endothelial dysfunction, ECs were
exposed to media containing sera from patients with aGVHD (n = 22) in the absence or
presence of DF and from patients that did not develop aGVHD (n= 13). ECs upregulated
adhesion molecules (vascular cell adhesion molecule 1, intercellular adhesion molecule
1), the adherence junction protein VE-cadherin, von Willebrand factor (VWF), and
Akt phosphorylation in response to aGVHD sera. These responses were suppressed
upon treatment with DF. In summary, DF inhibits vascular angiogenesis and endothelial
activation induced by sera from aGVHD patients. Our results support the view that DF
has notable positive effects on endothelial biology during aGVHD.
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INTRODUCTION
Hematopoietic cell transplantation (HCT) has demonstrated to
be an effective treatment for various hematological and non-
hematological diseases. Allogeneic HCT (allo-HCT) is associated
with various early complications, among which acute graft-vs.-
host disease (aGVHD) is the major cause of morbidity and
mortality after this treatment (1–5). aGVHD is characterized
by tissue and organ injury mainly affecting the liver, gut, and
skin (1). First-line treatment for patients undergoing aGVHD is
limited to corticosteroid therapy and immunosuppressive drugs,
such as calcineurin or mTOR inhibitors (1, 6, 7). Although
aGVHD progression can be partly or completely reverted
through the effects of these therapies on immune cells, they have
a detrimental impact on the endothelium (8).
The endothelial cells (ECs) that cover the vascular tree
are directly exposed to all the damaging factors occurring
during the onset and development of aGVHD. Our group
has previously demonstrated that allo-HCT is associated with
endothelial dysfunction (9, 10) and that endothelial damage
is aggravated with the development of aGVHD. Humoral
factors in the sera of allo-HCT recipients developing aGVHD
induced a marked proinflammatory and prothrombotic state
in cultured ECs (11). Plasma levels of von Willebrand
factor (VWF) and tumor necrosis factor receptor 1 were
higher in patients developing aGVHD than in allo-HCT
recipients not developing this complication. Other endothelial
damage markers, including angiopoietin-2, were increased
even in pretransplant patients who later developed aGVHD,
corroborating that the endothelium plays a role in the
pathogenesis of aGVHD (12). In addition, it has been considered
that angiogenesis, the formation of new blood vessels, might play
a major role in aGVHD development. It has been demonstrated
that, in the early inflammatory phase of GVHD, there is a
noticeable neovascularization that facilitates the migration of
inflammatory cells to target organs (13). Together, these findings
highlight the endothelium as a potential target for new therapies
to prevent and treat aGVHD (11, 14, 15).
Defibrotide (DF), an endothelial-protective drug (16), has
demonstrated to be effective in the prevention and treatment
of veno-occlusive disease/sinusoidal obstruction syndrome
(VOD/SOS), an early complication of HCT proven to be of
endothelial origin (17). Our previous studies demonstrated the in
vitro preventive effect of DF on the development of endothelial
damage in association with HCT (18) and the mechanisms of
action involved (19). DF, designated as an orphan drug for the
Abbreviations: aGVHD, acute graft-vs.-host disease; allo-HCT, allogeneic
hematopoietic cell transplantation; DF, defibrotide; DF-PT, defibrotide—
prophylaxis plus treatment; DF-T, defibrotide—therapeutic; EC, endothelial
cell; ECM, extracellular matrix; HCT, hematopoietic cell transplantation;
HMEC-1, human microvascular endothelial cells; HUVEC, human umbilical
vein endothelial cells; ICAM-1, intercellular adhesion molecule 1; MFI, mean
fluorescence intensity; SEM, standard error of the mean; TNFR1, tumor
necrosis factor receptor 1; VCAM-1, vascular cell adhesion molecule 1;
VOD/SOS, veno-occlusive disease/sinusoidal obstruction syndrome; VWF,
von Willebrand factor.
prevention of aGVHD, is currently being evaluated for GVHD
prevention in a clinical trial in adults (20).
The effect of DF has never been evaluated in an in vitro
aGVHD-related endothelial damage scenario. The present study
aimed to explore the effect of DF on endothelial cell proliferation
and tube formation and its potential as a prophylactic or/and
therapeutic agent for aGVHD-associated endothelial damage.
MATERIALS AND METHODS
Endothelial Cell Culture
Primary human umbilical vein endothelial cells (HUVEC) were
used to assess DF effect in proliferation and tube formation
assays. Human microvascular endothelial cells (HMEC-1)
(ATCC, Manassas, VA, USA) were used to investigate DF
effect on a GVHD-endothelial dysfunction in vitro model.
HUVEC were cultured in endothelial basal medium 2 (Lonza,




epidermal growth factor, hydrocortisone, GA-1000 (gentamicin,
amphotericin-B), 2% fetal bovine serum, vascular endothelial
growth factor, human basic fibroblast growth factor, R3 insulin
growth factor-1, ascorbic acid, and heparin. HMEC-1 were
grown in MCDB131 (Gibco-BRL, Madrid, Spain) medium
supplemented with 15% fetal bovine serum, 4% L-glutamine, 1%
penicillin-streptomycin (Gibco-BRL), 1µg/ml hydrocortisone
(Sigma-Aldrich, Madrid, Spain), and 10 ng/ml epidermal growth
factor (BD Biosciences, Erembodegem, Belgium). Both HUVEC
andHMEC-1 were cultured under humidified conditions at 37◦C
and in the presence of 5% CO2.
MTT Proliferation Assay
The proliferation rate of cells was assessed by the 3-[4,5-
dimethylthiazole-2-yl]-2,5-diphenyltetrazoliumbromide (MTT)
assay using the MTT Cell Proliferation Assay Kit (ATCC).
HUVEC were seeded in three 96-well plates (Sarstedt,
Nümbrecht, Germany) at 1–2 × 104 cells/well in 100 µl of
EGM-2. DF was added at 10, 100, or 500µg/ml. The first two
concentrations (10 and 100µg/ml) were selected due to their
clinical relevance (21, 22) and the last one (500µg/ml) to analyze
if maximum concentrations, not expected in the clinical routine,
have an additional effect. Then, the plates were incubated at 37◦C
for 24 h (D+ 1), 48 h (D+ 2), or 72 h (D+ 3), and 10 µl of MTT
reagent was added to each well. After 3 h, 100 µl of Detergent
Reagent was added to each well, and the plates were incubated
in the dark (3–4 h or overnight) until the precipitated formazan
crystals were dissolved. The absorbance at 570 nm was measured
using a SpectraMax Plus 384mL plate reader (Molecular Devices,
San Francisco, CA, USA). The mean value from quadruplicate
readings was determined.
Tube Formation Assay
The angiogenic activity of cells was determined by a tube
formation assay. Forty microliters of defrosted Matrigel R©
(Corning, Corning, NY, USA) was pipetted into the wells of a
96-well plate (Sarstedt), using a cut 10- or 100-µl pipette tip.
The plate was left to stand for 30–45min until the Matrigel
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was solidified. HUVEC (1 × 104 cells) in 100 µL of medium
containing DF at different concentrations were added to
each well. Cells incubated in EGM-2 and endothelial basal
medium 2 medium were used as a positive and negative control,
respectively. Tube formation was evaluated every hour, and after
6 h, micrographs were taken of three to five random fields per
well. The micrographs were analyzed using the Angiogenesis
Analyzer software developed by Gilles Carpentier (http://
image.bio.methods.free.fr/ImageJ/?Angiogenesis-Analyzer-for-
ImageJ&lang=en) in ImageJ Fiji (Bethesda, Rockville, MD,
USA) (23). The following features were assessed: number of
junctions, number of master junctions, number of segments,
number of master segments, number of meshes, mean mesh
size, and total meshes area. The mean value from quadruplicate
readings from two independent experiments was determined
for each parameter. Student’s unpaired t-test was applied for
the statistical analysis of all data using the statistics program
GraphPad Prism, version 4.02 (GraphPad Software Inc., La Jolla,
CA, USA). The values were adjusted to the positive control
and shown as percentage; the value of the positive control was
adjusted to 100%. Values were shown as mean ± standard error
of the mean (SEM).
Exposure of Endothelial Cells in Culture to
aGVHD Media
The effect of DF on aGVHD was assessed in vitro. HMEC-
1 (24) were incubated in growth medium supplemented with
20% of serum pools, each pool containing combinations of
sera from five different patients. Serum samples were collected
from patients with aGVHD on the day of diagnosis. For
experimental treatments, DF (100µg/ml) was added in two
modalities: (i) prophylaxis plus treatment (DF-PT), in which
ECs were incubated with DF 24 h before exposure to aGVHD
medium, and then fresh DFwas added withmedium replacement
every 24 h, and (ii) therapeutic (DF-T), in which ECs were
exposed to aGVHD medium, and DF was added 24 h later and
at growth medium replacement every 24 h. The control group
consisted of serum samples from allo-HCT recipients that did not
develop aGVHD (NoGVHD).
Patients and Specimen Collection
Patients undergoing allo-HCT at the Hospital Clinic of Barcelona
were included consecutively between 2008 and 2010. The
experimental group consisted of patients who developed aGVHD
grade II–IV within the first 3 months post allo-HCT (aGVHD
group, n = 22). The control group consisted of 13 patients
without aGVHD (NoGVHD group). Blood samples were
collected on the day of aGVHD diagnosis (before any change in
treatment) for the aGVHD group and on day 21 post allo-HCT
for the NoGVHD group. Patients with other early complications
associated with allo-HCT such as VOD/SOS, thrombotic
microangiopathy, capillary leak syndrome, or engraftment
syndrome were excluded for this study. Serum was obtained by
centrifugation at 2,500 rpm for 15min and was stored at −80◦C.
Patient characteristics are provided in Table 1.
TABLE 1 | Characteristics of patients with or without acute GVHD.
Groups GVHD NoGVHD
Patients










Sibling (% by group) 8 (36) 11 (85)
Unrelated (% by group) 14 (64) 2 (15)
Conditioning
MAC (% by group) 12 (54) 9 (69)







Onset day, median (range) 16 (7–28) NA
Chronic GVHD
>at day+180 (% by group) 10 (78) 6 (46)
*One case with CD34+ positive selection.
AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; NHL, non-Hodgkin’s
lymphoma; HL, Hodgkin’s lymphoma; PCD, plasma cell disease; CLL, chronic
lymphocytic leukemia; PLL, prolymphocytic leukemia; MAC, myeloablative conditioning;
RIC, reduced intensity conditioning; CyA, cyclosporine; MTX, methotrexate; MMF,
mycophenolate mofetil; Rapa, rapamicine; Tacro, tacrolimus.
Immunofluorescence Analysis
The expression of the adhesion molecules intercellular adhesion
molecule 1 (ICAM-1) and vascular cell adhesion molecule 1
(VCAM-1) on the cell surface, VE-cadherin at cell junctions,
and VWF in the extracellular matrix (ECM) was assessed
by immunofluorescence. HMEC-1 monolayers were incubated
in medium containing 20% pooled serum from the aGVHD
group, in the absence or presence of DF (DF-PT or DF-
T), and from NoGVHD group in eight-well microplates
(Nunklabtech, Madrid, Spain) for 48 h. ECs were fixed with
4% paraformaldehyde and incubated with specific monoclonal
antibodies to VCAM-1 (MA5-11447, 1/10; Invitrogen, Carlsbad,
CA, USA) and ICAM-1 (sc-107, 1/50; SantaCruz Biotech, Dallas,
TX, USA) or permeabilized (0.05% Triton X-100, 3min at room
temperature) and then incubated with a specific monoclonal
antibody to VE-cadherin (ab33168, 1/1,000; Abcam, Cambridge,
UK) or a specific polyclonal antibody to VWF (A0082, 1/2,000;
Dako/Agilent, Santa Clara, CA, USA), at room temperature for
1 h. Then, the cells were incubated with secondary antibodies
conjugated with Alexa Fluor 488 or 594 (Molecular Probes,
Eugene, OR, USA) at room temperature for 1 h. Cell monolayers
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were evaluated using a DM4000 B epifluorescence equipped
microscope and images captured through a video camera (Leica,
Barcelona, Spain). Analysis of fluorescence was carried out using
ImageJ Fiji software in 20 fields per coverslip, by independent
technicians blinded to the treatments.
Reactivity of the ECM Generated by
HMEC-1 Exposed to Study Conditions
ECs were cultured for 7 days on 18 × 18 mm2 coverslips in
six-well plates in medium supplemented with 20% serum pools.
The monolayers were exposed to 9% ethyleneglycoltetraacetic
acid at 37◦C for 1 h to remove ECs. To evaluate the reactivity of
the ECM toward circulating platelets, the ECM-coated coverslips
were perfused with citrated whole blood from healthy donors
in a parallel-plate perfusion chamber (shear rate of 800/s,
5min). After perfusion, the coverslips were fixed with 0.5%
glutaraldehyde at 4◦C and stained with 0.02% toluidine blue.
Images were captured using the DM4000 B epifluorescence
microscope. The surface covered by platelets (%) was quantified
en face in 20 fields per well using ImageJ Fiji by independent
technicians blinded to the treatments.
Western Blotting Analysis of
Phosphorylated Intracellular Proteins
Confluent EC monolayers, after starving with medium
containing 2% serum for 24 h, were exposed to the
serum pools under study with or without DF for 15min.
The ECs were lysed with Laemmli’s buffer (68.5mM
tris[hydroxymethyl]aminomethane-HCl, 2% sodium dodecyl
sulfate, 10% glycerol, 5mM β-mercaptoethanol, and 0.003%
bromophenol blue) containing 2mM sodium orthovanadate,
and 0.625 mg/ml N-ethylmaleimide. Proteins were resolved by
10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis
and transferred to nitrocellulose membranes (BioRad, Hercules,
Canada), which were probed with specific antibodies to
phosphorylated and unphosphorylated Akt, p38 MAPK, Erk1/2,
and SAPK/JNK (Cell Signaling Technology, Danvers, MA, USA).
Activation of proteins induced by NoGVHD sera was used
as control.
Statistical Analysis
Data are reported as the mean ± SEM. Data from aGVHD and
NoGVHD exposure experiments following a normal distribution
were analyzed by paired t-tests. Data from proliferation and
tube formation experiments were analyzed by unpaired t-tests.
All statistical analyses were conducted using GraphPad Prism,
version 4.02. P < 0.05 was considered significant.
Ethical Aspects
Informed consent for blood utilization was obtained from all
patients. The study was approved by the Ethics committee of
the Hospital Clinic of Barcelona (CEIC 2008/3353) and was
carried out in accordance with the principles of the Declaration
of Helsinki.
RESULTS
DF Suppresses EC Proliferation and Tube
Formation
As aGVHD has been associated with angiogenesis, we
investigated the effect of DF on the angiogenic potential of
ECs. First, we assessed the impact of DF on EC proliferation
by MTT assay. DF reduced EC proliferation in a time- and
dose-dependent manner (Figure 1). Of note, even at the
lowest concentration of 10µg/ml, DF significantly inhibited
EC proliferation. The reduction in the proliferation was more
notable at 100µg/ml (Figures 1B,C corresponding to MTT assay
day+ 2 and day+ 3), and no differences were observed between
100 and 500 µg/ml concentrations.
Next, we assessed the impact of DF on the angiogenic activity
of ECs by a tube formation assay. Cells were incubated in the
presence of 10, 100, or 500µg/ml DF in a 96-well plate coated
with Matrigel and analyzed after 6 h (micrographs in Figure 2).
DF significantly suppressed tube formation in a dose-dependent
manner for all features assessed: junctions (Figure 2A), master
FIGURE 1 | Defibrotide (DF) suppresses endothelial cell (EC) proliferation. An 3-[4,5-dimethylthiazole-2-yl]-2,5-diphenyltetrazolium bromide (MTT) assay was used to
quantify the effect of DF (10, 100, or 500µg/ml) for (A) 24 h (D + 1), (B) 48 h (D + 2), or (C) 72 h (D + 3) on EC proliferation. Bar diagrams represent the optical
density (OD) normalized to control data (%) expressed as the mean ± SEM of three experiments. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
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FIGURE 2 | Defibrotide (DF) suppresses endothelial cell (EC) tube formation. Representative images of angiogenic activity of ECs by a tube formation assay incubated
with DF at different concentrations. Bar diagrams represent different characteristics measured during tube formation: numbers of (A) junctions and (B) master
junctions, numbers of (C) segments and (D) master segments, and (E) number, (F) size, and (G) area of meshes, as indicated. Data are expressed as the mean ±
SEM of three experiments. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
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junctions (Figure 2B), segments (Figure 2C), master segments
(Figure 2D), meshes (Figure 2E), mean mesh size (Figure 2F),
and total meshes area (Figure 2G). Thus, DF significantly
suppressed EC proliferation and tube formation in vitro.
DF Prevents aGVHD Serum-Induced
Expression of Adhesion Molecules and
VE-Cadherin on ECs
To analyze the effect of soluble factors present in aGVHD patient
serum on ECs, HMEC-1 were cultured with pooled aGVHD or
NoGVHD serum samples for 48 h, and the expression of surface
proteins was analyzed by immunofluorescence. VCAM-1 and
ICAM-1 levels were significantly increased in the presence of
aGVHD serum compared to NoGVHD serum (Figure 3). The
mean fluorescence intensity (MFI of eight different experiments)
for VCAM-1 and ICAM-1 was 41.9 ± 3.1 and 34.3 ± 3.3,
respectively, in the presence of aGVHD serum vs. 27 ± 3.2
and 22.3 ± 3.2, respectively, in NoGVHD (P < 0.05 and P
< 0.01, respectively). To analyze whether DF can suppress the
aGVHD-induced upregulation of adhesion molecule expression,
we incubated ECs with aGVHD serum and DF in two regimens:
(i) prophylaxis plus treatment (DF-PT), in which ECs were
incubated with DF 24 h before exposure to aGVHD medium,
and then fresh DF was added with medium replacement every
24 h; and (ii) therapeutic (DF-T), in which ECs were exposed
to aGVHD medium, and DF was added 24 h later and at
growth medium replacement every 24 h. Figure 3 shows that
aGVHD serum-induced expression of VCAM-1 and ICAM-1
was significantly suppressed in the DF-PT group (to 37.1 ± 2.1
and 24.8± 3, respectively, P < 0.05) and the DF-T group (to 31.7
± 4.1 and 26.6± 2.4, respectively, P < 0.01).
Next, we analyzed the expression of VE-cadherin, an
adherence junction protein involved in angiogenesis and vascular
integrity, on ECs exposed to aGVHD or NoGVHD serum.
aGVHD serum enhanced VE-cadherin expression compared to
NoGVHD serum (MFI of eight different experiments, 15.14 ±
1.34 vs. 8.3 ± 2, P < 0.05). DF suppressed the VE-cadherin
upregulation in the prophylactic as well as the therapeutic setting
(DF-PT, 12.8± 2.1; DF-T, 11.5± 1.1, P < 0.05) (Figure 4). Thus,
DF reduced aGVHD serum-induced upregulation of adhesion
molecule and VE-cadherin expression on ECs in vitro.
DF Inhibits the Release of VWF From ECs
to the ECM
To investigate the potential antithrombotic effect of DF,
either DF-PT or DF-T, in aGVHD endothelial damage, VWF
expression in ECM generated by ECs grown in the presence
FIGURE 3 | Defibrotide (DF) has an anti-inflammatory effect on endothelial cells (ECs) activated and injured after exposure to acute graft-vs.-host disease (aGVHD)
serum. Representative images of (A) vascular cell adhesion molecule 1 (VCAM-1) and (B) intercellular adhesion molecule 1 (ICAM-1) expression on EC surfaces in
response to aGVHD serum collected on the day of onset in the absence (GVHD-NoDF) or presence of DF (prophylaxis and treatment, GVHD + DF-PT; treatment,
GVHD + DF-T). An image representative of results with NoGVHD medium is also included. Bar diagrams show the quantitative analysis of VCAM-1 and ICAM-1 for
GVHD-NoDF (black bars), GVHD + DF-PT (gray bars), GVHD + DF-T (dashed bars), and NoGVHD (white bars). Values represent mean ± SEM of MFI from eight
different experiments. *P < 0.05, **P < 0.01. Original magnification, 400× for all micrographs.
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FIGURE 4 | Defibrotide (DF) attenuates the increase in VE-cadherin expression on the surface of endothelial cells (ECs) exposed to acute graft-vs.-host disease serum.
VE-cadherin staining in ECs exposed to aGVHD serum in the absence (GVHD-NoDF) or presence of DF. An image representative of results with NoGVHD medium is
also included. Bar diagrams show the quantitative analysis of VE-cadherin expression for GVHD-NoDF (black bar), GVHD + DF-PT (gray bar), GVHD + DF-T (dashed
bar), and NoGVHD (white bar). Values indicate the mean ± SEM of MFI from eight different experiments. *P < 0.05. Original magnification, 400× for all micrographs.
of aGVHD or NoGVHD with or without DF was evaluated by
immunofluorescence. aGVHD serum enhanced VWF expression
compared to NoGVHD serum. The MFI of VWF, based on eight
different experiments, was 47.1 ± 5.6 for aGVHD vs. 31.9 ± 2.1
for NoGVHD (P < 0.01). Both DF-PT and DF-T significantly
suppressed VWF production, as indicated by MFIs of 37.4 ± 5.2
for DF-PT (P < 0.05) and 40.1± 5.9 for DF-T (Figure 5A).
DF Reduces the Increased Reactivity of the
ECM Toward Platelets Caused by Exposure
to aGVHD Serum
The effects of aGVHD serum and DF on ECM thrombogenicity
were studied under flow conditions. ECMs generated by ECs
grown in the presence of aGVHD or NoGVHD serum for 7 days
were exposed to circulating citrated blood from healthy donors,
and the surface covered by platelets was determined. The covered
surface (expressed in percent with respect to the total area of the
field analyzed, mean ± SEM, n = 8) was higher in the aGVHD
than in the NoGVHD group (38.4 ± 1.3 vs. 27 ± 1%, P <
0.01). DF-PT and DF-T significantly reduced surface coverage
to 30.4 ± 0.8% (P < 0.001) and to 32.1 ± 2.6% (P < 0.05),
respectively (Figure 5B).
DF Suppresses the Activation of Akt in ECs
Exposed to Serum From aGVHD Patients
The effects of aGVHD serum and DF on phosphorylation-
mediated activation of Akt, p38 MAPK, SAPK/JNK, and Erk1/2
were investigated by Western blotting. Akt phosphorylation was
significantly higher in cells exposed to aGVHD serum (fold
increase of 2.1 ± 0.3 in aGVHD vs. NoGVHD, P < 0.01). DF-
PT and DF-T significantly suppressed Akt phosphorylation in
response to aGVHD serum to 1.4± 0.2 and 1.6± 0.4, respectively
(Figure 6A). Similar trends were observed for p38, SAPK/JNK,
and Erk1/2, with fold increases of 1.46 ± 0.2, 1.36 ± 0.3, and 1.4
± 0.1 in aGVHD vs. NoGVHD, respectively. DF-PT reduced the
activation of p38, SAPK/JNK, and Erk1/2 to 1.3 ± 0.1, 1.13 ±
0.1, and 1.05 ± 0.1, respectively, and DF-T to 1.14 ± 0.16, 1.1 ±
0.06, and 1.37 ± 0.05, respectively (Figures 6B–D). Differences
between groups were only statistically significant for Akt.
DISCUSSION
We investigated the effect of DF on angiogenesis and its potential
preventive and restorative effects on endothelial injury caused by
aGVHD in an in vitro cell culture model. Experiments performed
to explore the effect of DF on angiogenesis showed that this
compound suppressed both proliferation and tube formation
capability in ECs. In addition, DF prevented and partially
reversed the endothelial inflammatory and prothrombotic
phenotypes induced by aGVHD serum. Interestingly, our in
vitro experiments demonstrated that DF is capable of restoring
endothelial damage when administered therapeutically. Our
results suggest a potential role of this drug as a prophylactic
and therapeutic agent for endothelial dysfunction associated
with aGVHD.
Owing to advances in the knowledge of aGVHD
pathophysiology in the last decade, the vascular endothelium
was identified as a new target for the prevention and treatment
of this complication (6, 15, 25–28). In the initial phases of
aGVHD development, angiogenesis precedes key processes, such
as inflammatory cell infiltration in typical aGVHD target organs
(29). However, blood vessels suffer fibrosis and rarefaction during
later stages of aGVHD due to the attack of alloreactive donor
T cells on the vasculature (14, 30). Inhibition of angiogenesis
during the early phases of aGVHDmay suppress the recruitment
of infiltrating leukocytes and, consequently, inflammation,
and thus may improve aGVHD (13, 29). Moreover, there is
evidence for the association between angiogenesis and the
expression of VE-cadherin, the main endothelial cell-to-cell
junction transmembrane protein that functions in vascular
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FIGURE 5 | Defibrotide (DF) reduces von Willebrand factor (VWF) expression and platelet adhesion on extracellular matrix (ECM) produced by endothelial cells (ECs)
exposed to aGVHD serum. (A) Micrographs showing expression of VWF on ECM produced by ECs exposed to aGVHD serum in the absence (GVHD-NoDF) or
presence of DF (DF-PT and DF-T). An image representative of results with NoGVHD medium is also included. Bar diagrams show the quantitative analysis of VWF
expression for GVHD-NoDF (black bar), GVHD + DF-PT (gray bar), GVHD + DF-T (dashed bar), and NoGVHD (white bar). Data are the mean ± SEM of MFI from eight
different experiments. *P < 0.05. Original magnification, 400× for all micrographs. (B) Representative images showing platelet adhesion after exposing ECM
produced under the indicated conditions to flowing blood (800/s, 5min). Bar diagrams show the surface covered by platelets (%) for GVHD-NoDF (black bar) GVHD +
DF-PT (gray bar), GVHD + DF-T (dashed bar), and NoGVHD (white bar). Data are the mean ± SEM of MFI from eight different experiments. *P < 0.05, **P < 0.001.
Original magnification, 200× for all micrographs.
morphogenesis and endothelial survival, on ECs (31, 32). In
this regard, Medinger et al. (33) reported higher microvessel
density and VE-cadherin expression in bone marrow sections
from patients with aGVHD than from patients without aGVHD.
In line herewith, we also found that VE-cadherin expression
was elevated in ECs exposed to aGVHD serum. In addition,
VE-cadherin was clearly downregulated by DF, mostly when ECs
were incubated with DF after 24 h of exposure to aGVHD serum.
The effect of DF on angiogenesis has been controversial. On
the one hand, DF has been shown to bind to and protect basic
fibroblast growth factor, a key angio-protective protein, thus
promoting EC mitogenesis in vitro (34), and to stimulate hepatic
sinusoidal EC angiogenesis in a dose-dependent manner (35).
On the other hand, it has been demonstrated that DF directly
interferes with EC migration and tube formation in vitro and in
animal models (36). Our results regarding new vessel formation
and VE-cadherin expression support the antiangiogenic role of
this drug.
The current study also provided new evidence indicating that
the treatment of ECs with DF is also effective in restoring the
inflammatory phenotype induced by aGVHD. The exposure of
ECs to pooled sera from aGVHD recipients induced increases in
cell-surface expression of the adhesion receptors VCAM-1 and
ICAM-1. DF had an anti-inflammatory effect as it suppressed the
expression of these receptors upon therapeutic and prophylactic
plus therapeutic administration. This strategy has already been
explored in the context of aGVHD; studies in mouse models have
shown that suppression of effector T cell recruitment by blocking
chemokine receptors and their ligands might be an interesting
approach to reducing GVHD (37–39).
ECs grown in the presence of sera from HCT recipients
generate an ECM enriched with VWF and tissue factor, which are
responsible for increased reactivity toward circulating platelets
(9). This prothrombotic phenotype was even more notable
in ECs exposed to sera from aGVHD patients than in ECs
exposed to NoGVHD serum. DF was able to suppress this
overproduction and/or release of VWF to the ECM. These
results are in line with the antithrombotic–thrombolytic behavior
of DF demonstrated in several experimental models (16)
and with results from clinical trials that demonstrated that
DF restores the thrombolytic–fibrinolytic balance in patients
suffering from VOD/SOS (40). DF has been also proposed for
the treatment of thrombosis associated with various pathologies,
including cerebral malaria, in which DF treatment leads to the
maintenance of thrombomodulin and the suppression of platelet
aggregation (41).
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FIGURE 6 | Defibrotide (DF) suppresses the activation of Akt in endothelial cells (ECs) exposed to serum from aGVHD patients. ECs were exposed for 15min to
aGVHD serum in the absence (GVHD-NoDF) or presence of DF (DF-PT and DF-T) to evaluate the effect of DF on the phosphorylation of (A) Akt (P-Akt), (B) p38 MAPK
(P-p38), (C) SAPK/JNK (P-SAPK/JNK), and (D) Erk1/2 (P-Erk1/2) by Western blotting. Images are representative of four experiments. Bar diagrams represent the
increases in phosphorylation with respect to the phosphorylation levels in cells exposed to NoGVHD serum. Data are the mean ± SEM from four different experiments
**P < 0.01. Results corresponding to NoGVHD are represented by a dotted line.
Sera from aGVHD patients disrupted endothelial homeostasis
and induced strong activation of the PI3K-Akt-mTOR stress-
signaling pathway. DF suppressed phosphorylation-dependent
Akt activation nearly to control levels. Akt is related to processes
devoted to EC stabilization during a dysfunctional state (42, 43),
and its dysregulation has been extensively studied in aGVHD,
although not in endothelium. PI3K/Akt pathway inhibitors can
interfere with T cell activation, and their therapeutic utility in
aGVHD has been explored (44, 45). The endothelial damage
caused by leukocyte transmigration implies the activation of
the inflammatory protein p38, the apoptosis-related protein
SAPK/JNK, and the cell proliferation, differentiation, and
survival protein Erk1/2 (46). In the current study, all these
proteins were consistently, to different extents, more strongly
activated in cells exposed to aGVHD serum than in cells exposed
to NoGVHD serum. DF prevented and reduced the activation of
all these proteins.
The present study demonstrated that DF inhibits EC
proliferation and tube formation. Considering that angiogenesis
precedes the onset of aGVHD, our results suggest that DF
might be useful for the prevention and treatment of aGVHD.
In addition, DF ameliorates the dysfunctional endothelial
phenotype caused by aGVHD serum by preventing inflammatory
and prothrombotic cell reactions and suppresses the activation
of the stress-related protein Akt. Interestingly, DF is able to
restore established endothelial damage. The present study was
performed in vitro, and more research is needed to corroborate
our findings. However, our results warrant further study of the
usefulness of DF for the prevention and treatment of aGVHD.
Clinical trials on aGVHD prophylaxis by DF are currently going.
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